These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16193831)

  • 1. Angiotensin-receptor blockers: benefits beyond lowering blood pressure.
    Silverstein RL; Ram CV
    Cleve Clin J Med; 2005 Sep; 72(9):825-32. PubMed ID: 16193831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin receptor blockers. Applications beyond hypertension.
    Jacobs TF; Ramsey LA
    Adv Nurse Pract; 2005 Jan; 13(1):27-30. PubMed ID: 15679288
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanisms for the clinical benefits of angiotensin II receptor blockers.
    Schmieder RE
    Am J Hypertens; 2005 May; 18(5 Pt 1):720-30. PubMed ID: 15882557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with the use of angiotensin receptor blockers in patients with cardiovascular, cerebrovascular and renal diseases.
    Chrysant SG
    Curr Clin Pharmacol; 2006 May; 1(2):139-46. PubMed ID: 18666366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal and stroke protection in hypertensive patients at CV risk.
    Cardiovasc J Afr; 2007; 18(5):337, 340. PubMed ID: 17985036
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview.
    Wang JG; Li Y; Franklin SS; Safar M
    Hypertension; 2007 Jul; 50(1):181-8. PubMed ID: 17502490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Have angiotensin receptor blockers lived up to expectations?
    Fitchett D
    Can J Cardiol; 2005 May; 21(7):569-75. PubMed ID: 15940354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candesartan: widening indications for this angiotensin II receptor blocker?
    Mendis B; Page SR
    Expert Opin Pharmacother; 2009 Aug; 10(12):1995-2007. PubMed ID: 19563275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
    Abassi Z; Winaver J; Feuerstein GZ
    Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oncology-related issues of angiotensin-receptor blockers].
    Telekes A; Kiss I
    Orv Hetil; 2015 Mar; 156(11):423-30. PubMed ID: 25749535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II antagonists--therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy.
    Ribeiro AB
    Curr Med Res Opin; 2006 Jan; 22(1):1-16. PubMed ID: 16393425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering.
    Miyata T; van Ypersele de Strihou C
    Nephrol Dial Transplant; 2006 Apr; 21(4):846-9. PubMed ID: 16476717
    [No Abstract]   [Full Text] [Related]  

  • 15. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Debate concerning the optimal blockage of the renin-angiotensin system].
    Choukroun G
    Nephrol Ther; 2010 Jan; 6 Spec No 1():H1-9. PubMed ID: 20129454
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure.
    Aksnes TA; Flaa A; Strand A; Kjeldsen SE
    J Hypertens; 2007 Jan; 25(1):15-23. PubMed ID: 17143167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
    Shionoiri H; Yasuda G; Takizawa T; Shionoiri F
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741
    [No Abstract]   [Full Text] [Related]  

  • 19. Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials.
    Flaa A; Aksnes TA; Strand A; Kjeldsen SE
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):451-61. PubMed ID: 17489670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.